Neville Rodie & Shaw Inc. Reduces Stock Holdings in AbbVie Inc. $ABBV

Neville Rodie & Shaw Inc. reduced its position in shares of AbbVie Inc. (NYSE:ABBV) by 16.6% in the second quarter, HoldingsChannel reports. The firm owned 88,895 shares of the company’s stock after selling 17,684 shares during the quarter. AbbVie makes up 1.4% of Neville Rodie & Shaw Inc.’s investment portfolio, making the stock its 17th largest position. Neville Rodie & Shaw Inc.’s holdings in AbbVie were worth $22,369,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in ABBV. Vanguard Group Inc. boosted its holdings in shares of AbbVie by 1.7% in the fourth quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company’s stock worth $41,306,353,000 after buying an additional 3,032,438 shares during the last quarter. State Street Corp increased its holdings in AbbVie by 1.4% during the fourth quarter. State Street Corp now owns 80,940,931 shares of the company’s stock valued at $18,494,193,000 after buying an additional 1,119,274 shares during the last quarter. Geode Capital Management LLC raised its position in AbbVie by 10.4% in the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock worth $10,179,099,000 after acquiring an additional 4,190,487 shares during the period. Bank of America Corp DE raised its position in AbbVie by 1.4% in the fourth quarter. Bank of America Corp DE now owns 25,824,399 shares of the company’s stock worth $5,900,617,000 after acquiring an additional 356,394 shares during the period. Finally, Norges Bank purchased a new position in shares of AbbVie during the 4th quarter worth $5,865,055,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reported strong second-quarter results, with revenue up 10.2% year over year and adjusted earnings per share exceeding consensus estimates. Growth from Skyrizi, Rinvoq and neuroscience products helped offset the continuing decline of Humira. AbbVie: Strong Q2 And New Catalysts Keep Me Bullish
• Positive Sentiment: Cantor Fitzgerald raised its AbbVie price target from $265 to $285 and maintained an “overweight” rating, reflecting confidence in the company’s growth outlook and pipeline.
• Positive Sentiment: New oncology opportunities could provide additional long-term growth. AbbVie’s telisotuzumab adizutecan is cited as an emerging targeted treatment in esophageal cancer, while the late-stage ABBV-706 trial is testing another potential therapy in small-cell lung cancer. Esophageal Cancer Market Outlook
• Neutral Sentiment: Analyst commentary remains broadly constructive, with some estimates suggesting shares could approach $300, supported by AbbVie’s dividend profile and the performance of newer growth products. AbbVie Quietly Solved Its Biggest Problem—Now What?
• Negative Sentiment: The Apogee Therapeutics acquisition is reducing projected 2026 earnings per share while increasing research and development costs. Although AbbVie raised its revenue outlook, the earnings dilution and weaker near-term guidance have prompted investor caution. ABBV Q2 Earnings Call Balances Growth With Apogee Dilution

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on ABBV shares. HSBC reissued a “buy” rating and set a $300.00 price objective on shares of AbbVie in a research report on Monday, July 6th. Guggenheim raised their target price on AbbVie from $249.00 to $261.00 and gave the stock a “buy” rating in a report on Thursday, July 9th. Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 5th. Evercore set a $235.00 price target on AbbVie in a report on Friday, May 15th. Finally, Royal Bank Of Canada upped their price target on AbbVie from $260.00 to $280.00 and gave the stock an “outperform” rating in a research report on Friday, July 10th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and a consensus target price of $271.48.

AbbVie Price Performance

Shares of NYSE:ABBV opened at $244.62 on Tuesday. The company has a market capitalization of $432.19 billion, a P/E ratio of 69.10, a P/E/G ratio of 0.83 and a beta of 0.30. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $267.47. The firm’s 50 day simple moving average is $239.67 and its two-hundred day simple moving average is $224.25.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 466.39%. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the prior year, the company posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, sell-side analysts anticipate that AbbVie Inc. will post 14.12 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.8%. AbbVie’s dividend payout ratio is currently 195.48%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.